INSTITUTIONAL DIGITAL REPOSITORY

Targets and strategies for vaccine development against SARS-CoV-2

Show simple item record

dc.contributor.author Malik, J.A.
dc.contributor.author Mulla, A.H.
dc.contributor.author Farooqi, T.
dc.contributor.author Pottoo, F.H.
dc.contributor.author Anwar, S.
dc.contributor.author Rengasamy, K.R.R.
dc.date.accessioned 2021-02-18T10:34:57Z
dc.date.available 2021-02-18T10:34:57Z
dc.date.issued 2021-02-18
dc.identifier.uri http://localhost:8080/xmlui/handle/123456789/1720
dc.description.abstract The SARS-CoV-2, previously called a novel coronavirus, that broke out in the Wuhan city of China caused a significant number of morbidity and mortality in the world. It is spreading at peak levels since the first case reported and the need for vaccines is in immense demand globally. Numerous treatment and vaccination strategies that were previously employed for other pathogens including coronaviruses are now being been adopted to guide the formulation of new SARS-CoV-2 vaccines. Several vaccine targets can be utilized for the development of the SARS-CoV-2 vaccine. In this review, we highlighted the potential of various antigenic targets and other modes for formulating an effective vaccine against SARS-CoV-2. There are a varying number of challenges encountered during developing the most effective vaccines, and measures for tackling such challenges will assist in fast pace development of vaccines. This review will give a concise overview of various aspects of the vaccine development process against SARS-CoV-2, including 1) potential antigen targets 2) different vaccination strategies from conventional to novel platforms, 3) ongoing clinical trials, 4) varying challenges encountered during developing the most effective vaccine and the futuristic approaches. en_US
dc.language.iso en_US en_US
dc.subject Vaccine en_US
dc.subject COVID-19 en_US
dc.subject Clinical trials en_US
dc.subject SARS-CoV-2 vaccine en_US
dc.subject Pandemic en_US
dc.subject Antigen targets en_US
dc.title Targets and strategies for vaccine development against SARS-CoV-2 en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account